FDA conducted 1,927 facility inspections globally in 2024, and issued Warning Letters following 42% of them. Between 2022 and 2024, FDA conducted 114 surprise or unannounced inspections at Indian pharma facilities specifically — 94 of which resulted in Form 483 observations.
Two real, recent cases
Granules India Ltd. (Aug–Sept 2024)
A 10-day FDA inspection produced a 26-page Form 483 citing "manipulating and destroying GMP data" — a data-integrity finding, not a manufacturing-quality one.
Chemspec Chemicals Pvt. Ltd. (Jul–Aug 2025)
Inspectors found manufacturing without batch records, destruction of original cGMP documents, and retroactive ("back-dated") completion of production records.
Both cases share a pattern: the underlying manufacturing process may or may not have been the actual problem — the finding was about the record of the process, not the process itself. This is the core lesson most "audit prep" content misses.
Inspection-readiness is a daily operating state
The most sophisticated framing of FDA preparation isn't a pre-visit checklist — it's the recognition that inspection-readiness has to be the default state of the quality system, not a condition achieved through a focused sprint before an anticipated visit. An unannounced inspection, by definition, doesn't give you the sprint. If your CAPA backlog, calibration status, and document control are only audit-ready right before a scheduled visit, they're not actually audit-ready.
What this means in practice
- Audit trails that are always intact — not reconstructed from emails and memory when a 483 response is due.
- CAPA effectiveness checks completed as items close, not backfilled when someone notices they're missing.
- Calibration and validation status current at all times, checkable in seconds, not assembled from a filing cabinet.
- Document control that prevents an outdated SOP from ever being on the floor in the first place — not a process for catching it after the fact.
The India-specific angle
Most generic "FDA audit prep" content is written for a US audience and doesn't address the specific enforcement reality Indian manufacturers face — a genuinely high rate of surprise inspections, and findings that increasingly focus on data integrity rather than product quality alone. Preparing for the audit you'll actually get means building a system where the record can't lie, not one where you hope nobody looks too closely.
Ready to see this in your own lab? Book a free ValiCore demo.